Nanoteknoloji Bazlı İlaç Taşıma Sistemlerinin Göze İlaç Uygulamalarında, Transkleral Geçiş Üzerine Etkisinin Değerlendirilmesi
Üst veriTüm öğe kaydını göster
Chitosan nanoparticles were synthesized and bevasizumab was loaded to this chitosan nanoparticles in the present thesis. Characterization of bevacizumab loaded chitosan nanoparticles were made and the size of the bevacizumab loaded chitosan nanoparticles were measured between the range of 80-380 nm in Atomic force microscope and zeta sizer. Drug loading capacity was measured as 38±22.In in vitro studies it was observed that amount of drug release was increased after fifth day of injection and continued during 3 weeks. In vivo studies of these bevacizumab loaded chitosan nanoparticle were studied. Loaded nanoparticles were injected as subtenon injections to rabbit eyes. No infectious or inflamatory reactions were developed during follow up period. Immunohistochemical sections showed some degree transport of bevacizumab loaded chitosan nanoparticles transport through sclera. After subtenon bevacizumab loaded chitosan nanoparticle injections serum and vitreus samples were obtained from the rabbits at first, third, fifth and seventh days. The values compared to those of rabbits that were applied free subtenon bevacizumab injection. Elevation of vitreus bevacizumab levels were observed earlier in bevacizumab loaded chitosan nanoparticle injected rabbits compared to free bevacizumab injected rabbits. Serum bevacizumab levels of bevacizumab loaded chitosan nanoparticle injected rabbits were lower that those of free bevacizumab injected rabbits.